Add BrightSurf on Google Email

Science News for January 25, 2007


Fungal factories may save hemlock forests

Researchers at the University of Vermont have developed a 'whey-based fungal micro-factory' to combat the eastern hemlock tree's decline due to an exotic pest. The approach involves spraying a sweet whey solution with targeted fungus into infected forests, promoting self-replication and reducing pesticide use.

JCI table of contents: January 25, 2006

Researchers found that increased expression of HO-1 and administration of carbon monoxide protected mice from MS. In contrast, mice lacking HO-1 developed more severe disease. The study suggests modulating HO-1 expression or administering carbon monoxide may be useful therapeutic strategies for treating patients with MS.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJan 25, 2007

Drug strategy makes cancer genes get lost in translation

A new strategy for fighting cancer aims to make its genes get lost in translation, silencing oncogenes by targeting weak messenger RNAs. The researchers discovered a small molecule that effectively inhibits the translation of these weak mRNAs, leading to the decline of cancer-promoting proteins.

SourceCell Press·JournalCell·DateJan 25, 2007

Stem cells cultured from human bone marrow behave like those derived from brain tissue

Researchers at Cedars-Sinai Medical Center successfully cultured stem cells from human bone marrow that can differentiate into neurons and other central nervous system cells. These cells exhibit behaviors similar to those derived from brain tissue, suggesting a promising approach for treating brain disorders and tumors.

SourceCedars-Sinai Medical Center·JournalJournal of Neuroscience Research·DateJan 25, 2007

New antibody for EGFR causes lung cancer regression

Researchers have discovered a new antibody that effectively regresses lung tumors in mice with two types of lung cancer driven by mutant forms of the EGFR protein. The study highlights the potential therapeutic benefits of this antibody, ch806, for treating patients with specific lung cancer mutations.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJan 25, 2007